The company reported yesterday on the submission of an initial consulting folder to the FDA and positive results in its first pre-clinical trial for the treatment of ALS
NESS ZIONA, Israel--(BUSINESS WIRE)--Israeli biotechnology company Kadimastem (TASE:KDST) announces today that only one day after approaching the FDA regarding the cellular treatment that it is developing for ALS, an encouraging response was received. Based on the quality of the data presented, the FDA recommends rapidly moving forward in the approval process towards product development and safety (towards clinical trials).
” The submission was prepared by the company's development team, accompanied by Gsap, headed by Dr. Sigalit Ariely-Portnoy.
Help employers find you! Check out all the jobs and post your resume.
NESS ZIONA, Israel--(BUSINESS WIRE)--Israeli biotechnology company Kadimastem (TASE:KDST) announces today that only one day after approaching the FDA regarding the cellular treatment that it is developing for ALS, an encouraging response was received. Based on the quality of the data presented, the FDA recommends rapidly moving forward in the approval process towards product development and safety (towards clinical trials).
” The submission was prepared by the company's development team, accompanied by Gsap, headed by Dr. Sigalit Ariely-Portnoy.
Help employers find you! Check out all the jobs and post your resume.
